IGMS

IGM Biosciences, Inc.

7.38 USD
+0.10 (+1.37%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

IGM Biosciences, Inc. stock is down -19.96% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 June’s closed higher than May. In the last 1 Unusual Options Trades, there were 1 CALL. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
22 May 17:59 21 Jun, 2024 10.00 CALL 201 427

About IGM Biosciences, Inc.

IGM Biosciences, Inc. develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma.